Exit Mode
Firm intentionHealthcare25 June 2026

ENDRA Life Sciences Inc. to acquire ASP Isotopes Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
ENDRA Life Sciences Inc.
Target
ASP Isotopes Inc.
Deal value
Not disclosed
Announced
25 June 2026
Status
Firm intention
Sector
Healthcare
Country
United States
Consideration
Not stated

Sources

SEC_EDGAR_8KSEC_EDGAR_8K
What we know

ENDRA Life Sciences Inc. has agreed to acquire ASP Isotopes Inc. in a strategic transaction announced on 25 June 2026. Both companies are based in the United States and operate within the healthcare sector. The deal structure involves the transfer of shares as the sole form of consideration. No specific monetary value has been disclosed for this acquisition, and the financial terms remain private. The transaction represents a significant move within the industry, combining two entities in the US market. As of the latest available information, the deal is at the firm intention stage. There is no reported completion date for the transaction at this time. The parties have indicated a clear intent to proceed, but the finalisation of the deal remains pending. This acquisition is expected to consolidate positions within the healthcare landscape, although specific strategic details have not been provided in the public record. The market awaits further updates regarding the regulatory and procedural steps required to close the transaction.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

2 updates
  1. CMA invitation to comment

    ENDRA Life Sciences Inc. M&A filing involving ASP Isotopes Inc.

    Item 7.01 . Regulation FD Disclosure. As previously disclosed, on June 25, 2026, ASP Isotopes Inc., a Delaware corporation (“ASPI” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ENDRA Life Sciences Inc., a Delaware corporation (“ENDRA”), Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of the Compan

    Source
  2. Firm intention

    ENDRA Life Sciences Inc. firm intention to acquire ASP Isotopes Inc.

    Item 1.01. Entry into a Material Definitive Agreement. First Amendment to Agreement and Plan of Merger As previously disclosed, on June 25, 2026, ENDRA Life Sciences Inc., a Delaware corporation (“ENDRA” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ASP Isotopes Inc. (“ASPI”), a Delaware corporation, Noble Africa LLC, a Delaware limited liab

    Source

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare dealsMore 2026 dealsMore strategic acquisition dealsMore from ENDRA Life Sciences Inc.All M&A deals

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

ENDRA Life Sciences Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive
Get the Exit Mode Toolkit, $97